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A causal relationship between Mitofusin (MFN) 2 gene mutations and the hereditary
axonal neuropathy Charcot-Marie-Tooth disease type 2A (CMT2A) was described over
15 years ago. During the intervening period much has been learned about MFN2
functioning in mitochondrial fusion, calcium signaling, and quality control, and the
consequences of these MFN2 activities on cell metabolism, fitness, and development.
Nevertheless, the challenge of defining the central underlying mechanism(s) linking
mitochondrial abnormalities to progressive dying-back of peripheral arm and leg nerves
in CMT2A is largely unmet. Here, a different perspective of why, in humans, MFN2
dysfunction preferentially impacts peripheral nerves is provided based on recent insights
into its role in determining whether individual mitochondria will be fusion-competent
and retained within the cell, or are fusion-impaired, sequestered, and eliminated by
mitophagy. Evidence for and against a regulatory role of mitofusins in mitochondrial
transport is reviewed, nagging questions defined, and implications on mitochondrial
fusion, quality control, and neuronal degeneration discussed. Finally, in the context
of recently described mitofusin activating peptides and small molecules, an overview
is provided of potential therapeutic applications for pharmacological enhancement of
mitochondrial fusion and motility in CMT2A and other neurodegenerative conditions.
Keywords: mitochondrial fusion, mitophagy, mitochondrial transport, Charcot-Marie-Tooth disease,
neurodegeneration
OVERVIEW OF MITOFUSINS
Mitofusin (MFN) 1 and MFN2 are closely related dynamin family GTPases encoded by nuclear
genes, but located on outer mitochondrial membranes. Originally described by Margaret Fuller and
colleagues as the human homologs of Drosophila fuzzy onion (Fzo) (Santel and Fuller, 2001; Santel
et al., 2003), MFN1 and MFN2 differ in catalytic GTPase activity essential for mitochondrial fusion
(Ishihara et al., 2004), in their ability to localize at endo/sarcoplasmic reticulum and mediate trans-
organelle calcium signaling (De Brito and Scorrano, 2008; Chan, 2012; Naon et al., 2016; Seidlmayer
et al., 2019; Dorn, 2020), and in their proposed roles mediating mitophagic mitochondrial
removal (Chen and Dorn, 2013; Gong et al., 2015). Nevertheless, MFN1 and MFN2 have largely
overlapping functions in the sequential tethering and fusion of mitochondria and appear to be
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almost interchangeable in this regard. Thus, forced expression
or pharmacological activation of either MFN1 or MFN2 can
overcome mitochondrial fusion defects resulting from haplo-
insufficiency in MFN1 or MFN2 null cells (Chen et al., 2003;
Rocha et al., 2018), or from dominant suppression by MFN2
mutants (Detmer and Chan, 2007; Rocha et al., 2018; Zhou
et al., 2019). Yet, detailed structures of individual mitofusin
proteins located on outer mitochondrial membranes, of the
oligomeric MFN structures that presumably mediate membrane
deformation required for membrane fusion, and of trans MFN-
MFN dimers that extend outward from mitochondria into
cytosolic space and tether mitochondria together, are currently
lacking. Consequently, much of the structural information about
MFNs and the macromolecular complexes they form is either
hypothetical or inferential (Koshiba et al., 2004; Brandt et al.,
2016; Franco et al., 2016; Mattie et al., 2018; Rocha et al., 2018;
Li et al., 2019).
By comparison, our phenomenological understanding of
mitofusin pathophysiology is quite detailed, having been
informed by gene knockout experiments (Chen et al., 2003,
2007, 2010, 2011, 2014; Lee et al., 2012; Sebastian et al., 2012,
2016; Kasahara et al., 2013; Song et al., 2014, 2015, 2017;
Mourier et al., 2015; Boutant et al., 2017; Ramirez et al.,
2017; Zhao et al., 2018; Bell et al., 2019; Han et al., 2020)
and gain- or loss-of-function manipulation with MFN-specific
mini-peptides and small molecules (Franco et al., 2016; Rocha
et al., 2018). Collectively, this body of work supports three
general conclusions: 1. Mitofusin insufficiency or impaired
activity is broadly detrimental; 2. Absence of MFN2 is more
deleterious than absence of MFN1; and 3. The consequences
of impaired MFN-mediated mitochondrial fusion, mitophagy,
and inter-organelle communication differ, depending upon
cellular context.
Results of MFN deletion using in vitro cell and in vivo
mouse models have built a solid foundation for interrogating
the consequences of mitofusin deficiency produced by naturally
occurring genetic MFN mutations in humans. Only two human
diseases are unambiguously attributed to functional MFN
deficiency: Charcot-Marie-Tooth disease type 2A (CMT2A)
that is almost always mono-allelic (i.e., heterozygous) with
autosomal dominant inheritance (vide infra), and multiple
symmetric lipomatosis that has been described with bi-allelic
(i.e., homozygous or compound-heterozygous) MFN2 mutations
(Rocha et al., 2017; Capel et al., 2018). Because very little is known
about MFN-induced lipomatosis, here I focus on CMT2A.
MFN2 MUTATIONS AND
CHARCOT-MARIE-TOOTH DISEASE
Charcot-Marie-Tooth disease was originally described in 1886
as “progressive muscular atrophy” by French neurologists
Jean-Martin Charcot and Pierre Marie, and the English
neurologist Howard Henry Tooth. As currently used in the
clinic, the term CMT generally describes a large number
of clinically heterogenous and genetically diverse inherited
peripheral neuropathies (Fridman et al., 2015). CMT type 2A
(CMT2A), defined by its causal MFN2 gene mutations (Zuchner
et al., 2004), is the second most common form of CMT
(Cornett et al., 2016) and is remarkable for early onset and
rapid progression during childhood. In the largest reported
United States study (n = 99 patients from Wayne State University
plus 27 patients from the United Kingdom) (Feely et al., 2011),
the average age of onset for CMT2A was 4.4 years (vs 41 years
for other forms of CMT2); most CMT2A patients were non-
ambulatory by 20 years of age. These findings are consistent with
the International Neuropathies Consortium cohort of >1,400
CMT patients (including n = 910 CMT1 and 237 CMT2)
(Fridman et al., 2015). MFN2 mutations comprise ∼6% of
familial CMT (∼22% of familial CMT2) (Bombelli et al., 2014;
Choi et al., 2015) and are, depending upon nationality, the
second or third most common cause of CMT, after the PMP22
duplication/deletion and GJB1 mutations that cause CMT1A
(Fridman et al., 2015; Ando et al., 2017; Hoebeke et al., 2018;
Yoshimura et al., 2019). Among patients with CMT2A, the
majority of MFN2 mutations affect the amino terminal GTPase
and mid-protein MFN2 coiled-coiled domains, with disease onset
in the first 2 years of life and an aggressive clinical course.
A few patients have mutations at the extreme MFN2 carboxyl
terminus and typically exhibit later onset (range 5–33 years
old) and milder disease (Feely et al., 2011; Stuppia et al., 2015;
Figure 1). Strikingly, CMT provoked by vincristine therapy
has been described in children treated for acute lymphoblastic
leukemia (Chauvenet et al., 2003), providing an example of gene-
environment interactions that can induce the clinical phenotype.
The prototypical CMT2A patient exhibits loss of sensory
and motor nerve function in the distal limbs (Bombelli et al.,
2014), but some patients additionally show evidence of laryngeal
paralysis (Zuchner et al., 2006), loss of visual acuity from
retinal degeneration (Chung et al., 2006; Verhoeven et al., 2006;
Zuchner et al., 2006; Feely et al., 2011), sensorineural hearing
loss (Nicholson et al., 2008), spinal cord atrophy (Bombelli
et al., 2014), and upper motor neuron signs (Vucic et al., 2003;
Chung et al., 2006; Rance et al., 2012), which support reports
of central nervous system involvement (Brockmann et al., 2008;
Boaretto et al., 2010; Milley et al., 2018). Proximal limb weakness,
in addition to classical distal limb involvement, is observed in
approximately one third of CMT2A patients (Bombelli et al.,
2014), and occurs earlier than in CMT1A. Clinical heterogeneity
observed in CMT2A has been attributed in part to the different
functional impact of multiple implicated MFN2 mutations:
GTPase and coiled-coiled domain mutations tend to induce
more severe and early onset disease whereas mutations in the
carboxy terminal domain tend to have later onset and milder
disease (Feely et al., 2011; Stuppia et al., 2015). However, even
within family members having the same MFN2 mutation there
can be inter-individual variability in disease manifestation and
progression (Chung et al., 2006; Bombelli et al., 2014).
An unequivocal diagnosis of CMT2A requires genetic testing
that identifies a causal MFN2 mutation in a suggestive clinical
context. Disease severity and progress can be monitored by
tests of neuromuscular integrity that reveal areflexia (from
lower sensory-motor nerve damage), loss of vibratory and
proprioceptive senses (Gemignani et al., 2004; Park et al., 2012),
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FIGURE 1 | MFN2 mutation class and possible mechanisms mediating CMT2A. (top) Schematic depiction of MFN2 protein showing globular GTPase domain
(green) and alpha helical coiled-coil stalk region (orange, yellow) and disease characteristics of respective mutations. CMT2A transgenic mice described herein
express MFN2 R94Q and T195M, which are within the GTPase domain. (bottom) Possible cellular mechanisms by which dominant suppression of normal MFN1
and MFN2 function by damaging MFN2 mutations might provoke disease.
muscle weakness and atrophy (especially in the tibialis
anterior muscle, resulting in foot-drop; Neves and Kok,
2011); neuroelectrophysiological testing shows normal nerve
conduction velocity with reduced compound motor activation
potentials (CMAP) (Harding and Thomas, 1980; Berciano et al.,
2017). Histologically, there is loss of large myelinated fibers
with partial regeneration, but normal myelin (Muglia et al.,
2001; Verhoeven et al., 2006); neuronal and skeletal muscle
mitochondria are abnormal on ultrastructural examination
(Verhoeven et al., 2006; Sole et al., 2009).
Although the genetic cause of CMT2A is, by definition,
mutational MFN2 dysfunction (Zuchner et al., 2004; Bombelli
et al., 2014), the functional consequences linking MFN2
dysfunction to the cellular pathology underlying neuronal
die-back and neuromuscular degeneration remain unclear
(reviewed in Filadi et al., 2018). Mechanisms that have been
proposed include: 1. Disrupted mitochondrial fusion and loss
of fusion-related homeostatic repair (Chen and Chan, 2006;
Pareyson et al., 2015); 2. Related interruption of mitochondrial-
endoplasmic reticular communications that variably perturb
calcium crosstalk and phospholipid/cholesterol synthesis (Larrea
et al., 2019); 3. Dysregulated mitochondrial quality control with
mitochondrial depletion or retention of cytotoxic senescent
and damaged mitochondria (Rizzo et al., 2016; Filadi et al.,
2018); and 4. Interrupted mitochondrial trafficking through
neuronal axons (Baloh et al., 2007; Pareyson et al., 2015;
Crunkhorn, 2018; Figure 1). While it seems likely that
all of these mechanisms contribute in a combinatorial way
to CMT2A neuromuscular disease, disrupted mitochondrial
trafficking is particularly intriguing as a contributory mechanism
because a transportation defect could explain why CMT2A
preferentially affects the longest peripheral nerves innervating
lower and upper limbs; travel delays have greater impact
on long journeys.
In vivo PATHOPHYSIOLOGY PROVOKED
BY HUMAN CMT2A MFN2 MUTANTS
EXPRESSED IN MICE
Two CMT2A MFN2 mutants, MFN2R94Q and MFN2T105M,
have been expressed in mice by various groups attempting
to evoke features of peripheral axonopathy similar to the
human condition. Both of these mutations are in the MFN2
GTPase domain, and expression of either dominantly inhibits
mitochondrial fusion and induces mitochondrial clustering
in fibroblasts (Detmer and Chan, 2007). It is notable that
CMT2A MFN2 mutants induce phenotypes that recapitulate
some features of human CMT2A (detailed below), whereas
expressing wild-type (WT) MFN2 in the same experimental
systems is well tolerated. Absence of pathology provoked by
overexpressed WT MFN2 in mice suggests greater cell capacity
to compensate for mitofusin gain of function than for mitofusin
inhibition or gene deletion.
The first reported CMT2A MFN2 mutant mouse was
developed in David Chan’s laboratory and used a motor-neuron
specific HB9 promoter to drive expression of a bi-cistronic
MFN2T105M/EGFP transgene in motor neurons (Detmer et al.,
2008; Figure 2). Because H9B gene activity is highest during
fetal development (Arber et al., 1999; Thaler et al., 1999), HB9-
MFN2T105M transgene expression in these mice decreased
after birth and was not detected from P10 (Detmer et al.,
2008). Thus, these mice reflect developmental motor neuron
phenotypes that are not reversible by perinatal extinction of
pathological MFN2 mutant expression. Nevertheless, histological
loss of motor neuron axons and mitochondrial dysmorphology
with uneven distribution throughout axons were associated in
homozygous transgenic mice with abnormal musculoskeletal
hindlimb development and loss of tibialis anterior muscle mass.
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These developmental mouse phenotypes are not typical for
human CMT2A in which the disease first manifests in early
childhood. Additionally, early transgene extinction does not
recapitulate the human genetic condition. Thus, the utility of
these mice, which are no longer available, was limited.
A ROSA-targeted flox-stop transgene approach to
MFN2T105M expression was more recently employed by
David Pleasure to work around potential transgene insertion
effects and avoid perinatal extinction of transgenes being driven
by developmentally important gene promoters (Bannerman
et al., 2016; Figure 2). A flox-stop MFN2 T105M transgene
was knocked into the genetically safe mouse Rosa26 locus
where its transcription is driven by the powerful hybrid CAG
(CMV enhancer fused to chicken beta-actin) promoter. A loxP-
flanked STOP cassette makes the MFN2 T105M transgene silent
until Cre-recombination. Thus, tissue-specific MFN2T105M
expression can be accomplished by combining the flox-stop
transgene with a tissue-specific Cre. Crossing the MFN2T105M
mice with nestin-Cre (expressed in neuroectoderm) provoked
gait abnormalities and hind-limb muscle (i.e., soleus and tibialis
anterior) muscle fiber atrophy with evidence for diminished
mitochondria in nerve axons. Surprisingly, in the 10 weeks old
male mice described, axon size and RotaRod latency (time before
falling off a rotating cylinder, which measures neuromuscular
functional integrity) were normal. The ROSA-STOP-(CAG-
MFN2T105M) mice are available from The Jackson Laboratory
(stock number 025322) and have also been used in combination
with motor neuron-specific HB9-Cre to elicit mitochondrial
hypomotility in sciatic nerve axons studied ex vivo (Rocha
et al., 2018); an in vivo phenotype of the latter mice has
not been reported.
MFN2R94Q was first expressed in mice by Chrast and
Martinou using the neuron-specific enolase promoter, designated
“MitoCharc” mice (Cartoni et al., 2010; Figure 2). Heterozygous
(MitoCharc1) and homozygous (MitoCharc2) mice exhibited
age-dependent (5 months) decreases in RotaRod latency with
gait abnormalities, associated at 1 year with axons having
smaller diameters and increased numbers mitochondria. In a
follow-up study, diminished mitochondrial fusion, impaired
mitochondrial-ER communication with induction of an ER
stress response, and defective mitochondrial transport were
all implicated in observed neuromuscular dysfunction. The
heterozygous MitoCharc1 mice are available from The Jackson
Laboratory (stock number 012812).
More recently, Robert Baloh transgenically expressed
MFN2R94Q in mice using a Thy1 promoter that expresses in
most neuronal cell types (Zhou et al., 2019; Figure 2). Compared
to other CMT2A mouse models, this one exhibits a constellation
of abnormalities that closely resembles neuromuscular pathology
in human CMT2A. In functional studies, compared to both
normal controls and WT MFN2 transgenic mice, MFN2
R94Q mice exhibited fewer rearing events on open field
testing, decreased RotaRod latency, and diminished grip
strength, all reflecting impaired motor function. Additionally,
MFN2R94Q mice showed poor visual acuity by optokinetic
testing, recapitulating retinal (sensory neuron) involvement
sometimes seen in human CMT2A (Zuchner et al., 2006).
Histological studies showed axon degeneration and atrophy with
mitochondrial fragmentation and aggregation in the absence of
mitophagy. Importantly, forced concomitant expression of WT
MFN1 with MFN2R94Q prevented the CMT2A phenotypes,
suggesting a role for the putative imbalance between MFN1 and
MFN2 in CMT2A mitochondrial and neuromuscular defects.
However, the notion that correcting an MFN isoform imbalance
(and not simply restoring overall MFN expression/activity to
more normal levels) evoked phenotypic rescue in this mouse
requires that MFN2 expression fail to provide the same benefits
as MFN1 expression. Although the MFN2 rescue mice were
described, only a comparable rescue of body weight was reported;
functional neuromuscular phenotyping of mice expressing WT
MFN1 and MFN2R94Q is needed to address questions of
MFN subtype effects. All three mouse strains in this study are
available from The Jackson Laboratory (stock numbers 029745,
032728, and 033391).
Phenotypic heterogeneity in these CMT2A mice might be
the consequence either of the different transgenic systems used
to express mutant MFN2 (at different levels and in different
neuronal subtypes) or to the different MFN2 mutants examined.
Since the two versions of MFN2R94Q mice have different
phenotypes, it is the author’s opinion that transgene system,
rather than mutation identity, is likely the greatest source
of experimental variability. An obvious work-around that can
control for different transgene expression systems is to knock
human CMT2A mutations into analogous positions within
the mouse genome. Indeed, the knock-in approach has been
used to insert MFN2R94Q into the mouse genome (Strickland
et al., 2014). Heterozygous MFN2R94Q knock-in mice (i.e.,
that recapitulate the mono-allelic human condition) showed
decreased open field movement, but other read-outs of motor
dysfunction like RotaRod latency, grip strength, and beam
traversing, were normal. Also there was no evidence for sensory
neuron dysfunction in tests of thermal allodynia. Likewise, axon
diameter and mitochondrial movement in dorsal root ganglion
neurons were normal. By comparison, MFN2R94Q mice bred
to homozygosity died from unidentified reasons within 24 h
of birth. Thus, these MFN2 mutant knock-in mice have not
recapitulated seminal characteristics of human CMT2A. The
reasons why transgenic overexpression of MFN2R94Q evokes
CMT2A-like phenotypes in mice whereas a knock-in of the
same mutation failed to do so are not entirely clear. Since
expression level is a critical determinant of dysfunction provoked
by dominant inhibitory proteins, it is possible that mutant
transgenes were simply expressed at higher levels than the knock-
in mutant alleles.
Charcot-Marie-Tooth disease type 2A is typically a disease
of long peripheral nerves. In the classical presentation CMT2A
affected children do not manifest signs until the “toddler” stage
or somewhat later. The disease then progresses during childhood
and adolescence and stabilizes in young adulthood (Feely et al.,
2011; Fridman et al., 2015). If one views these data as a function of
patient size rather than age (which are obviously highly correlated
during childhood), the disease is silent in smaller humans,
progresses as they enlarge, and then stops progressing when
growth stops. Viewed in the context of characteristic involvement
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FIGURE 2 | Technical and phenotypic characteristics of published CMT2A mouse models. Mutant MFN2 transgenes (squares) were expressed using systems
shown in ovals. Resulting phenotypes are connected with arrows. References for each mouse are in parentheses.
of long nerves, disease progression as nerves elongate supports
a physical dimension to disease manifestation. If this is correct,
then mice may be resistant to knock-in attempts to provoke the
human disease because even their longest nerves (sciatic and
tail) are short in comparison with human peripheral nerves.
MFN2 mutant knock-ins of larger animal models (rats, dogs,
pigs, primates) would therefore be expected to more closely
reproduce clinical CMT2A.
MFN-MEDIATED FUSION, MITOPHAGY,
AND TRANSPORT IN DISEASE
As introduced above, it is widely accepted that mitochondrial
fusion is essential to cell health. MFN1 and MFN2 are necessary
for mitochondrial fusion, both as the initiators of enabling
mitochondria-mitochondria tethering and as the mediators of
outer membrane fusion. For these reasons, it is widely assumed
that CMT2A, the prototypical disease of MFN dysfunction, is
a disease of impaired mitochondrial fusion (Chan, 2012). Since
MFN1 can generally substitute for MFN2 as a mitochondrial
fusion factor (Detmer and Chan, 2007; Zhou et al., 2019), but
only MFN2 mutations cause disease, it is worth exploring how
impairment of other MFN2 functions might also contribute to
pathological phenotypes.
The underlying rationale for defective mitochondrial fusion
causing CMT2A is obvious: Mitochondrial fusion appears
essential to the health of all tissues and cell types, independent
of their mitochondrial density, morphology, or motility.
Accordingly, complete abrogation of mitochondrial fusion by
combined ablation of both MFN1 and MFN2 was detrimental to
neurons that contain small, highly motile mitochondria (Chen
et al., 2007), to cardiac and skeletal muscle that contain small,
but stationary mitochondria (Chen et al., 2010, 2011; Song
et al., 2015), as well as to fibroblasts whose mitochondria are
elongated and interconnected into structurally pliable networks
(Chen et al., 2003).
Mitochondrial fusion is an important mechanism by which
mitochondrial content exchange maintains biochemical and
genetic uniformity within the organelle collective. This process
of “complementation” moderates the number and impact of
mutations in the small mitochondrial genome (mtDNA) (Chan,
2012), which encodes 13 critical electron transport chain complex
proteins essential to normal mitochondrial respiratory function
(Chen et al., 2007, 2010, 2011). Moreover, the dynamic imbalance
resulting from reduced mitofusin activity or expression, thus
favoring mitochondrial fission over fusion, can lower the
threshold for apoptotic programmed cell death (Frank et al.,
2001; Sugioka et al., 2004). Given the apparent ubiquity and
importance of mitochondrial fusion demonstrated in vitro and
in multiple genetic mouse models, it seems paradoxical that
in human patients the damaging effects of CMT2A-linked
MFN2 mutations are restricted to distal neurons of the longest
peripheral nerves. If the pathophysiology relates exclusively to
impaired fusion, then one would predict that short and long
nerves, and central and peripheral nerves, and other tissues with
high mitochondrial density and metabolic demand (like cardiac
and skeletal muscle), would all be affected. And if CMT2A is only
caused by defective mitochondrial fusion, then severely damaging
MFN1 mutations should also cause a CMT2A-like syndrome. It
has been suggested that differences between MFN1 and MFN2
expression account for exclusivity of MFN2 mutations as causal
factors in disease. Thus, if MFN2 is expressed in neuronal cells at
levels far greater than MFN1, this could explain the unique role of
MFN2 (Lee et al., 2012; Zhou et al., 2019). However, this notion
has been difficult to validate at the protein level because of varying
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antibody affinities for the two mitofusins. Moreover, if increased
MFN2/MFN1 expression is a specific feature of the neurons
affected by CMT2A, it is hard to understand how this imbalance
provokes CMT2A-induced neuronal damage that increases with
distance from the spine, i.e., why within the same neuron the
distal axon dies back, but the proximal axon and soma are spared.
In this context it seems likely that other MFN2-mediated events,
in addition to altered fusion, contribute to CMT2A.
Mitophagy, which shares some of the same protein mediators
and can be co-regulated with apoptosis, can be considered as
a form of “programmed mitochondrial death” (Whelan et al.,
2012; Dorn and Kitsis, 2015). MFN2 plays a unique role in
mitophagy compared to MFN1, and mitophagic dysfunction may
also contribute to neuronal degeneration in CMT2A.
The classic mitophagy pathway is a mechanism for selective
removal of irreparably damaged mitochondria from cells via
the PINK1-Parkin pathway, as recently reviewed in detail
(Dorn, 2016; Pickles et al., 2018). An in vivo role played
by MFN2 as a signaling intermediate between mitochondrial
PINK1 kinase and the cytosolic E3 ubiquitin ligase Parkin was
described in neurons and cardiac myocytes (Lee et al., 2012;
Chen and Dorn, 2013; Chen et al., 2014; Song et al., 2015,
2017). Briefly, nuclear-encoded PINK1kinase is translated in
the cytosol and actively imported into mitochondria; in normal
mitochondria PINK1 is immediately degraded via targeted
proteolysis. Thus, healthy mitochondria contain little or no
PINK1 protein. However, PINK1 degradation is suppressed
in functionally impaired or damaged mitochondria, permitting
PINK1 to accumulate. When present, PINK1 phosphorylates its
many mitochondrial substrates, including at least three amino
acids on MFN2 (Chen and Dorn, 2013; Rocha et al., 2018). MFN2
phosphorylation by PINK1 promotes MFN2-Parkin binding
on the outer mitochondrial membrane, facilitating Parkin-
mediated ubiquitination of one hundred or more mitochondrial
outer membrane proteins (Sarraf et al., 2013). Ubiquitinated
mitochondrial outer membrane proteins attract autophagosomes
and stimulate autophagosomal engulfment of the damaged
organelle, thus initiating mitophagy (Pickles et al., 2018).
PINK1-phosphorylated MFN2 is not only a “Parkin receptor,”
but it loses the ability to promote mitochondrial fusion (Chen
and Dorn, 2013; Rocha et al., 2018). This binary functional
switching of MFN2 from mitochondrial fusion protein to
mitophagy effector serves to sequester organelles destined for
mitophagic elimination from fusing with healthy members of
the mitochondrial collective, thus preventing “mitochondrial
contagion” (Bhandari et al., 2014). In this context, it is reasonable
to postulate that fusion-impaired MFN2 mutants could also
be mitophagy-impaired. However, impaired mitophagy is not a
feature of CMT2A. Indeed, both an in vitro study of iPSC-derived
motor neurons derived from siblings harboring a MFN2A383V
mutation (Rizzo et al., 2016), and an in vivo mouse study of
MFN2R94Q (Zhou et al., 2019), suggest that mitophagy is either
not changed or is increased in experimental CMT2A, perhaps
as a compensatory reaction to respiratory dysfunction in fusion-
defective organelles.
Mitochondrial transport requires organelle coupling via
the ortholog of Drosophila Milton, Trak1, to dynein and
kinesin, the molecular motors that move cargo along cell
microtubular structures (Stowers et al., 2002). Because the Trak1-
dynein/kinesin-microtubule pathway is a general mechanism
for trans-cellular cargo transport, for mitochondria to be
transported as the cargo a mitochondrial Trak1 binding
protein Mitochondrial Rho GTPase 1 (Miro1) attaches and
detaches mitochondria from the cell transport apparatus
(Wang and Schwarz, 2009). By binding to Trak1, Miro1
protein located (along with MFN1 and MFN2) on outer
mitochondrial membranes can attach the mitochondria to
molecular motors of the transport apparatus, and release
the mitochondria where cytosolic calcium levels are locally
increased (Devine et al., 2016). Consistent with this mechanism,
Miro-deficient cells have impaired mitochondrial transport
(Lopez-Domenech et al., 2018).
Published data have implicated MFN proteins in
mitochondrial transport, which could explain selective die-
back of long peripheral nerves in CMT2A. However, a plausible
molecular mechanism by which mitofusins engage the transport
machinery has not been defined, and the relative roles of putative
MFN- vs canonical Miro-driven mitochondrial trafficking are
unclear. Evidence for diminished mitochondrial motility in
neurons expressing CMT2A MFN2 mutants is inferential (Baloh
et al., 2007; Misko et al., 2010; Rocha et al., 2018) and potentially
explainable by indirect effects of impaired mitochondrial
fusion (and resulting alterations in mitochondrial morphology,
connectivity, and respiratory function) on mitochondrial
motility. The observation that both mitofusins can interact with
Miro proteins when the protein pairs are co-expressed (Misko
et al., 2010) suggested direct interactions between MFN1 or
MFN2 and the canonical Miro-Trak mitochondrial transport
apparatus. Again however, because co-expressed proteins can
participate in non-physiological promiscuous interactions, and
co-immunoprecipitation may involve third unidentified protein
partners, these types of co-IP studies do not prove either a
naturally occurring or direct interaction between MFNs and
Miros. Thus, while published associations between mutational
or allelic loss-of-MFN function and mitochondrial dysmotility
suggest that mitofusins somehow either regulate or help mediate
mitochondrial transport, this notion requires unambiguous
delineation of the causal molecular events in the context of
endogenous proteins in relevant neuronal systems.
PHARMACOLOGICAL MITOFUSIN
ACTIVATION AS A RESEARCH TOOL
AND POTENTIAL CLINICAL
THERAPEUTIC
Until recently the only way to interrogate mitofusin function
was genetically, through gene deletion or overexpression of WT
or mutant MFNs. Several years ago, Franco et al. described an
MFN2-derived activating mini-peptide that, by competing with
endogenous peptide-peptide interactions constraining MFN1
and MFN2 into closed “inactive” conformations, induced a
more open and “active” conformation capable of promoting
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mitochondrial fusion (Franco et al., 2016). The MFN activator
peptide is useful as a research tool for in vitro studies of MFN
functioning (Zhou et al., 2019), but peptides are unwieldy as
clinical therapeutics because they are expensive to produce,
usually cannot be administered orally, and tend to be rapidly
eliminated. Thus, Rocha et al. used rational design to develop
small molecule peptidomimetics with even greater in vitro
potency than the original mitofusin activating peptide: First,
a minimally effective MFN activating peptide of 11 amino
acids was identified. Then, alanine scanning was used to
delineate the functionally important amino acids. Finally, a
pharmacophore model was used to perform an in silico screen
for commercially available compounds having similar structural
characteristics as the function-critical agonist peptide amino
acids. Biological screening of 55 such candidates identified two
with detectable agonist activity and de novo synthesis of so-called
“Franken-molecules” having different chemical moieties from
these fusogenic compounds led to a first-in-class small molecule
mitofusin agonist, Chimera B-A/l (Rocha et al., 2018). Chimera is
a potent mitochondrial fusogen (EC50 3–5 nM) lacking activity
for related dynamin-family proteins, which rapidly (<1 h)
normalized mitochondrial transport in ex vivo sciatic nerve
axons from CMT2A mice (Rocha et al., 2018). Because the
pharmacokinetic and in vivo pharmacodynamic characteristics
of Chimera B-A/l were not reported it is not clear whether this
compound will prove useful in vivo as a treatment for CMT2A.
Nevertheless, the possibility of using pharmacology, instead of or
in addition to genetic manipulation, to understand the various
roles played by mitofusins in cell biology and neurodegenerative
disease adds to the existing research tool kit and may hold
clinical promise.
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